Literature DB >> 19412008

Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.

Piotr Socha1, Andrea Horvath, Pietro Vajro, Piotr Dziechciarz, Anil Dhawan, Hania Szajewska.   

Abstract

BACKGROUND: Uncertainty exists regarding the treatment of patients with nonalcoholic fatty liver disease (NAFLD) who are unable to lose weight and/or change lifestyle. The present study assesses the effectiveness and safety of pharmacological and dietary supplement interventions for NAFLD.
METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched for randomized controlled trials (RCTs) both in adults and in children.
RESULTS: Fifteen (2 pediatric patients and 13 adults) RCTs met the inclusion criteria. A significant effect on normalization of alanine transaminase was found in patients treated with metformin compared with vitamin E, and in those treated with high-dose (3 g) carnitine vs diet. In contrast, there was no difference in patients treated with pioglitazone combined with vitamin E versus vitamin E alone, ursodeoxycholic acid (UDCA) combined with vitamin E or alone versus placebo, or UDCA versus combination of vitamin E and vitamin C, and in patients treated with vitamin E, probucol, N-acetylcysteine, low doses of carnitine, or Yo Jyo Shi Ko compared with placebo. Aspartate aminotransferase normalization was significantly higher in those treated with UDCA combined with vitamin E versus UDCA alone or placebo, and in those treated with metformin. Small number of subjects, high drop-out rates, and numerous interventions in 1 study limit the value of many studies. Only 7 RCTs analyzed biopsy specimens, but most of them have significant methodological limitations. Pioglitazone had reduced liver necrosis and inflammation in 1 large study.
CONCLUSIONS: Limited data do not allow one to draw firm conclusions on the efficacy of various treatments for NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412008     DOI: 10.1097/MPG.0b013e31818e04d1

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  32 in total

1.  Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment.

Authors:  B G P Koot; O H van der Baan-Slootweg; S Vinke; A E Bohte; C L J Tamminga-Smeulders; P L M Jansen; J Stoker; M A Benninga
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

2.  Pediatric obesity. An introduction.

Authors:  Jack A Yanovski
Journal:  Appetite       Date:  2015-03-30       Impact factor: 3.868

Review 3.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 4.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 5.  Gut microbiota and liver diseases.

Authors:  Masami Minemura; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 6.  Microbiota and nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Yuji Ogawa; Koichiro Wada; Atsushi Nakajima
Journal:  Semin Immunopathol       Date:  2013-12-14       Impact factor: 9.623

7.  Relationships of cardiorespiratory fitness with metabolic risk factors, inflammation, and liver transaminases in overweight youths.

Authors:  Dominique Bouglé; Gautier Zunquin; Bruno Sesbouë; Jean-Pierre Sabatier
Journal:  Int J Pediatr       Date:  2010-06-28

Review 8.  Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.

Authors:  Juan Du; Yan-Yan Ma; Chao-Hui Yu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

9.  Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice.

Authors:  Chih-Wen Lin; Hao Zhang; Min Li; Xiwen Xiong; Xi Chen; Xiaoyun Chen; Xiaocheng C Dong; Xiao-Ming Yin
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

Review 10.  Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease.

Authors:  Pietro Vajro; Giulia Paolella; Alessio Fasano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-05       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.